Corcept Therapeutics (CORT) Tops Q3 EPS by 13c, provides guidance
Tweet
Share
E-mailGet Alerts CORT Hot Sheet
Price: $117.17 +2.36%
Financial Fact:
Research and development: 7.05M
Today's EPS Names:
MSGM, SMID, VISL, More
Financial Fact:
Research and development: 7.05M
Today's EPS Names:
MSGM, SMID, VISL, More
Join SI Premium – FREE
Corcept Therapeutics (NASDAQ: CORT) reported Q3 EPS of $0.41, $0.13 better than the analyst estimate of $0.28. Revenue for the quarter came in at $182.5 million versus the consensus estimate of $171.98 million.
GUIDANCE:
Corcept Therapeutics sees FY2024 revenue of $675-700 million, versus the consensus of $661.1 million.
For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
- Kaiser Aluminum names Fred Stephan as CEO, effective November 2026
- Brookfield offers A$4.75/sh for Reliance Worldwide - Bloomberg
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
